Senseonics Inc. (SENS), a medical technology company, announced on Thursday the pricing of an underwritten public offering of 8 million shares of common stock at $5.00 per share. To certain investors, the company is offering pre-funded warrants to purchase up to 8 million shares of common stock at $4.99 per share.
Additionally, the company is offering underwriters an option to purchase up to 2.4 million shares at the public offering price.
The offering is expected to close on May 4, 2026. Gross proceeds from the offering are estimated at $80 million.
The company is currently developing Eversense, a continuous glucose monitoring (CGM) system for people with diabetes. This includes Eversense 365, and Eversense 3, and consists of sub-cutaneous sensors that communicates with a smart transmitter worn on the skin.
SENS is currently trading at $5.14, down 22.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.